Intervention C

Phase 3Small molecule

GSK

Intervention C is one of 55 small molecule programs targeting Psoriasis. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PsoriasisActive, not recruiting

Premature EjaculationActive, not recruiting

PsoriasisPhase 3

Active, not recruiting

Premature EjaculationPhase 1

Active, not recruiting

Competition

Competitive Landscape

605 competitors in Psoriasis

#DrugCompanyPhaseTrials

Stelara

Johnson & Johnson

Preclinical

37 2

Cosentyx

Novartis

Preclinical

53 3

Taltz

Eli Lilly

Preclinical

20 4

Bimzelx

UCB

Preclinical

17 5

Humira

CCelltrion

Preclinical

42 6

Ilumya

Sun Pharmaceutical Industries, Inc.

Preclinical

15 7

Intervention C

GSK

Phase 3

1 8

Raptiva

Roche

Preclinical

10 9

Remicade

OOrganon and Co

Preclinical

20 10

Siliq

BBausch Health Americas, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2034

N/ARecruiting

Effectiveness

NCT06808425

Clinical

Trials by Indication[1]

Premature Ejaculation1 trial

A Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment of Premature Ejaculation

Completed·PPlethora Solutions Ltd·Phase 1·NCT01184105·30 enrolled

Psoriasis1 trial

Efficacy and Safety Study of Subcutaneous Secukinumab in Treatment of Subjects With Moderate to Severe Chronic Plaque-type Psoriasis as Compared to Etanercept and Placebo.

Withdrawn· Novartis logo

Novartis·Phase 3·NCT01900782

Effectiveness1 trial

Intervention With Weighted Blankets for Children With ADHD and Sleep Problems: Implementation and Effectiveness

Recruiting·—·N/A·NCT06808425·200 enrolled

Hepatic Impairment1 trial

Fosamprenavir in Pts With Hepatic Impairment

Completed· GSK logo

GSK··NCT01054586·167 enrolled

Unspecified1 trial

A Safety and Tolerability Study of Administration of PSD502

Completed·PPlethora Solutions Ltd·Phase 1·NCT01183208·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Intervention C. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Intervention C compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Intervention C. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GSK company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: GSK

Intervention C

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2034

Trials by Indication[1]

Premature Ejaculation1 trial

Psoriasis1 trial

Effectiveness1 trial

Hepatic Impairment1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News